RxDoctor Payments Data

Mark Marchitto, MD

Dermatology · Cromwell, CTNPI 1134624000

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $171,601 of the $248,655 with a category attached, or 69.0%. LEO Pharma Inc. accounts for 77.0% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $126,732, more than ten times the $385 reported in 2022. Among dermatology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$248,655in general payments, 2019–2025

Across 721 payments — averaging $344.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma Inc.$191K
  • Pfizer$35K
  • Johnson & Johnson$5K
  • AbbVie$5K
  • Incyte Corporation$4K
  • UCB, Inc.$3K
  • plus $6K from 16 others

What the payments were for

  • Consulting fees$52,31221%
  • Speaking & faculty fees$171,60169%
  • Travel & lodging$8,0823%
  • Food & beverage$16,6497%
  • Education$110%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$248,655 in reported general payments places this provider in the 95th percentile of 222 dermatology providers in Connecticut.

See all dermatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$93,329
Medicare patients
268
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$244,419
AdbryTralokinumab-Ldrm11$41,336
Clobetasol Propionate72$2,623
Fluorouracil24$1,714
Ketoconazole111$1,282
Ciclopirox37$1,171
Erythromycin-Benzoyl PeroxideErythromycin/Benzoyl Peroxide12$1,137
Doxycycline Monohydrate33$923
Triamcinolone Acetonide105$853
Metronidazole24$800
Clindamycin Phosphate26$670
Betamethasone Dipropionate14$519
Fluocinonide19$509
Mupirocin67$479
Gabapentin17$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$191,406$41,33611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 dermatology providers in Connecticut.

Other dermatology in Cromwell

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →